Total Payments
$583.96
2024 Payments
$247.85
Companies
9
Transactions
19
Medicare Patients
9,260
Medicare Billing
$4.3M
Payment Breakdown by Category
Food & Beverage$583.96 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $583.96 | 19 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $114.71 | 5 | $0 (2024) |
| Allergan Inc. | $112.23 | 1 | $0 (2018) |
| Bausch & Lomb Americas Inc. | $108.46 | 1 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $96.03 | 4 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $53.18 | 3 | $0 (2020) |
| ABBVIE INC. | $44.94 | 2 | $0 (2024) |
| Biogen, Inc. | $20.80 | 1 | $0 (2022) |
| Apellis Pharmaceuticals, Inc. | $19.49 | 1 | $0 (2024) |
| Horizon Therapeutics plc | $14.12 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $247.85 | 7 | Bausch & Lomb Americas Inc. ($108.46) |
| 2023 | $89.33 | 4 | Regeneron Healthcare Solutions, Inc. ($61.06) |
| 2022 | $46.40 | 2 | Genentech USA, Inc. ($25.60) |
| 2021 | $19.16 | 1 | Regeneron Healthcare Solutions, Inc. ($19.16) |
| 2020 | $14.36 | 1 | Novartis Pharmaceuticals Corporation ($14.36) |
| 2019 | $38.82 | 2 | Novartis Pharmaceuticals Corporation ($38.82) |
| 2018 | $128.04 | 2 | Allergan Inc. ($112.23) |
All Payment Transactions
19 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $20.84 | General |
| Category: EYE CARE | ||||||
| 12/04/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $22.71 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/30/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: Ophthalmology | ||||||
| 06/24/2024 | Genentech USA, Inc. | Susvimo (Drug), Vabysmo | Food and Beverage | In-kind items and services | $25.94 | General |
| Category: Immunology and Ophthalmology | ||||||
| 05/21/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $24.10 | General |
| Category: EYE CARE | ||||||
| 05/08/2024 | Bausch & Lomb Americas Inc. | INFUSE (Device) | Food and Beverage | In-kind items and services | $108.46 | General |
| Category: Ophthalmology | ||||||
| 02/12/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $26.31 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/10/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $33.76 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/22/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $14.15 | General |
| Category: Immunology and Ophthalmology | ||||||
| 05/02/2023 | Horizon Therapeutics plc | TEPEZZA (Drug) | Food and Beverage | In-kind items and services | $14.12 | General |
| Category: TEPEZZA | ||||||
| 03/27/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $27.30 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/26/2022 | Genentech USA, Inc. | VABYSMO (Drug) | Food and Beverage | In-kind items and services | $25.60 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/13/2022 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $20.80 | General |
| 08/09/2021 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $19.16 | General |
| Category: OPHTHALMOLOGY | ||||||
| 03/06/2020 | Novartis Pharmaceuticals Corporation | BEOVU (Drug) | Food and Beverage | In-kind items and services | $14.36 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/11/2019 | Novartis Pharmaceuticals Corporation | BEOVU (Drug) | Food and Beverage | In-kind items and services | $20.98 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/15/2019 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $17.84 | General |
| 03/06/2018 | Allergan Inc. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $112.23 | General |
| Category: RETINA | ||||||
| 02/05/2018 | Regeneron Healthcare Solutions, Inc. | EYLEA AFLIBERCEPT INJECTION (Biological) | Food and Beverage | In-kind items and services | $15.81 | General |
| Category: OPHTHALMOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 2,098 | 5,188 | $4.8M | $857,115 |
| 2022 | 14 | 2,209 | 5,672 | $5.5M | $1.0M |
| 2021 | 15 | 2,575 | 6,568 | $6.6M | $1.3M |
| 2020 | 15 | 2,378 | 6,327 | $3.2M | $1.1M |
Total Patients
9,260
Total Services
23,755
Medicare Billing
$4.3M
Procedure Codes
57
All Medicare Procedures & Services
57 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 113 | 904 | $3.4M | $619,162 | 18.1% |
| 67028 | Injection of drug into eye | Office | 2023 | 220 | 876 | $403,036 | $71,794 | 17.8% |
| 92134 | Imaging of retina | Office | 2023 | 637 | 1,638 | $258,630 | $46,949 | 18.2% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 433 | 577 | $280,999 | $45,417 | 16.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 197 | 287 | $145,374 | $23,849 | 16.4% |
| J3590 | Unclassified biologics | Office | 2023 | 96 | 380 | $122,740 | $17,322 | 14.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 96 | 210 | $74,760 | $13,531 | 18.1% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 77 | 77 | $44,660 | $7,204 | 16.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 38 | 38 | $25,004 | $4,139 | 16.6% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 39 | 39 | $17,355 | $3,775 | 21.8% |
| 92250 | Photography of the retina | Office | 2023 | 117 | 121 | $18,271 | $2,961 | 16.2% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 15 | 20 | $4,060 | $649.21 | 16.0% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 20 | 21 | $2,079 | $363.85 | 17.5% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 118 | 998 | $3.8M | $712,780 | 18.9% |
| 67028 | Injection of drug into eye | Office | 2022 | 226 | 889 | $413,609 | $73,859 | 17.9% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 14 | 220 | $305,602 | $48,511 | 15.9% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 467 | 597 | $290,739 | $47,910 | 16.5% |
| 92134 | Imaging of retina | Office | 2022 | 654 | 1,693 | $267,378 | $47,744 | 17.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 197 | 281 | $142,186 | $24,657 | 17.3% |
| J3590 | Unclassified biologics | Office | 2022 | 97 | 391 | $124,855 | $17,376 | 13.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 99 | 238 | $84,728 | $15,315 | 18.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 53 | 53 | $34,874 | $6,334 | 18.2% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 68 | 68 | $39,440 | $5,850 | 14.8% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 53 | 56 | $24,920 | $5,121 | 20.5% |
| 92250 | Photography of the retina | Office | 2022 | 112 | 117 | $17,667 | $2,961 | 16.8% |
About Dr. David Schnitzer, MD
Dr. David Schnitzer, MD is a Retina Specialist healthcare provider based in Westerville, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1508832981.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Schnitzer, MD has received a total of $583.96 in payments from pharmaceutical and medical device companies, with $247.85 received in 2024. These payments were reported across 19 transactions from 9 companies. The most common payment nature is "Food and Beverage" ($583.96).
As a Medicare-enrolled provider, Schnitzer has provided services to 9,260 Medicare beneficiaries, totaling 23,755 services with total Medicare billing of $4.3M. Data is available for 4 years (2020–2023), covering 57 distinct procedure/service records.
Ad
Practice Information
- Specialty Retina Specialist
- Other Specialties Ophthalmology
- Location Westerville, OH
- Active Since 02/27/2006
- Last Updated 04/05/2017
- Taxonomy Code 207WX0107X
- Entity Type Individual
- NPI Number 1508832981
Products in Payments
- OZURDEX (Drug) $157.17
- INFUSE (Device) $108.46
- Vabysmo (Drug) $63.17
- EYLEA (Biological) $46.46
- BEOVU (Drug) $35.34
- EYLEA HD (Biological) $33.76
- Susvimo (Drug) $25.94
- VABYSMO (Drug) $25.60
- Syfovre (Drug) $19.49
- EYLEA AFLIBERCEPT INJECTION (Biological) $15.81
- TEPEZZA (Drug) $14.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.